How Testosterone Cypionate Affects Free Testosterone Levels

Updated May 25, 2026

Image: HealthRX.com clinical illustration

Testosterone cypionate is a long-acting testosterone ester (brand examples include Depo-Testosterone) given by intramuscular or subcutaneous injection, FDA-approved for testosterone replacement in men with confirmed hypogonadism. It is distinct from testosterone enanthate (a similar but not identical ester with a slightly different release profile) and from compounded or non-FDA-approved testosterone preparations sold outside a pharmacy setting.

In men with hypogonadism, testosterone cypionate raises both total and free (unbound, biologically active) testosterone. Free testosterone tends to rise more than total testosterone on a percentage basis because exogenous testosterone occupies sex hormone-binding globulin (SHBG) binding capacity and can also reduce hepatic SHBG production over time. This is an established pharmacologic pattern; the exact multiple of increase varies by patient, dose, injection frequency, and assay method, and precise figures reported in any single study should not be generalized to an individual reader without a clinician reviewing that patient's labs.

The core answer, and its boundary

Testosterone cypionate reliably increases free testosterone in hypogonadal men started on standard replacement doses, with measurable change within the first one to three weeks and a stable trough level typically reached after several dosing cycles (roughly 6 to 12 weeks). The rise in free testosterone is generally larger in proportion than the rise in total testosterone because SHBG saturation and SHBG suppression both push more testosterone into the unbound fraction. This pattern is well described in endocrinology and andrology literature; however, the exact fold-increase, peak values, and trough targets differ across studies and assay types, and a specific patient's response requires an individual lab trend rather than a population average.

Why free testosterone moves differently than total testosterone

Only a small fraction of circulating testosterone, roughly 1% to 3%, is free. Most of the rest is bound tightly to SHBG, with a smaller portion loosely bound to albumin (free plus albumin-bound testosterone is sometimes called "bioavailable testosterone"). SHBG has a finite number of binding sites. As testosterone cypionate injections raise circulating testosterone, those sites become increasingly occupied, and additional testosterone increasingly ends up in the free pool rather than being buffered by SHBG.

There is also observational and trial evidence that testosterone therapy can lower SHBG concentrations over months of treatment, which would further amplify the free testosterone response beyond what dose alone predicts. The direction of this SHBG effect is consistent across multiple studies of testosterone replacement, though the exact magnitude of SHBG suppression varies by population (age, body weight, liver and thyroid status) and should be treated as a general mechanism rather than a fixed percentage.

Free testosterone is the fraction that enters cells and activates the androgen receptor, which is why endocrinology guidance treats it as more clinically informative than total testosterone in men whose SHBG is abnormal, for example men with obesity, aging-related SHBG rise, liver disease, or thyroid dysfunction. In men with normal SHBG, total and free testosterone usually track closely enough that total testosterone alone is an adequate monitoring tool.

Time course: when does free testosterone actually rise

Testosterone cypionate is a depot injection with a terminal half-life on the order of about a week once released from the injection site. Practically, this means:

Free testosterone can begin rising within the first few days after the first injection.
A clinically meaningful increase is usually apparent within the first several weeks.
Steady-state trough levels, the level right before the next scheduled injection, generally stabilize after multiple dosing cycles, often cited as roughly 6 to 12 weeks, though this depends on dose and injection interval.

On a weekly injection schedule, testosterone (and free testosterone) typically peaks a few days after the injection and declines toward a trough just before the next dose. On a biweekly schedule, the peak-to-trough swing is wider, meaning free testosterone may be well above target shortly after injection and closer to pre-treatment levels just before the next one. This sawtooth pattern is the practical reason clinical guidance emphasizes drawing labs at a consistent, defined point in the cycle rather than at a random time.

Decision framework: what a free testosterone result should change

This is not a substitute for individualized dosing by a prescriber, but it summarizes the logic clinicians generally apply when interpreting a free testosterone result on testosterone cypionate.

Step 1: Confirm the draw was a trough, not a peak.

Weekly injection protocol: blood should be drawn on day 6 or 7, just before the next dose.
Biweekly injection protocol: blood should be drawn on day 12 to 14, just before the next dose.
If the draw timing is unknown or inconsistent with prior draws, treat the result as uninterpretable and repeat it correctly before changing dose.

Step 2: Confirm the assay type.

Equilibrium dialysis or a calculated free testosterone (from total testosterone, SHBG, and albumin) are the methods considered reliable.
Direct analog immunoassays for free testosterone are widely regarded as imprecise, particularly at low concentrations, and a low or high result from this method alone should prompt a repeat with a better method rather than an immediate dose change.

Step 3: Interpret the result against SHBG, not just an isolated number.

Free testosterone low, SHBG high (common with aging, some anticonvulsants, hyperthyroidism): total testosterone may look adequate while free testosterone is not. This favors a dose increase or a switch to a schedule with less peak-to-trough variability, guided by a clinician.
Free testosterone high, SHBG low (common with obesity, insulin resistance, or the SHBG-suppressing effect of testosterone itself): total testosterone may look modest while free testosterone is already adequate or high. This favors caution before increasing dose, and consideration of dose reduction if hematocrit or symptoms suggest excess.
Free testosterone in range but symptoms persist: the framework does not support attributing symptoms to testosterone dosing by default. Estradiol, sleep quality, thyroid function, and mood should be evaluated before adjusting the testosterone dose further.

Step 4: Check the safety panel alongside free testosterone.

Hematocrit, PSA (with a clinician's judgment on baseline and follow-up intervals), and estradiol are typically tracked alongside free testosterone.
A free testosterone result "in range" does not override a rising hematocrit; erythrocytosis is a recognized dose-limiting side effect of testosterone therapy and may require dose reduction, a change in injection frequency, or phlebotomy regardless of what the free testosterone number shows.

Step 5: Use consistent labs over time.

Free testosterone values from different laboratories and different assay methods are not directly comparable. A trend from the same lab, same assay, same trough timing is far more useful than a single value compared against a generic reference range.

Monitoring: what timing and assay choice actually require

A practical monitoring panel for a man on testosterone cypionate generally includes total testosterone, free testosterone (calculated or equilibrium dialysis), SHBG, estradiol, hematocrit, and PSA, checked together so that one number does not get interpreted in isolation.

General clinical practice checks levels within the first few months of starting or adjusting therapy, then at longer intervals once a stable, appropriate dose is established. Exact intervals (for example, "6 to 8 weeks" during titration versus "annually" once stable) are guideline-dependent and should be confirmed with the prescribing clinician rather than treated as fixed rules, since practice varies by patient risk factors and by the specific formulation and schedule used.

Factors that change how much free testosterone rises

Not every patient on the same dose reaches the same free testosterone level. Several factors plausibly change the response, based on the mechanism and population-level associations described in the endocrinology literature, though individual prediction still requires actual lab trends:

Body weight and SHBG at baseline. Men with obesity often have lower baseline SHBG, so the same milligram dose of testosterone cypionate may produce a smaller percentage rise in free testosterone relative to a leaner man with higher baseline SHBG, because there is less SHBG capacity left to saturate.
Age. SHBG tends to rise with age, which can make an older man's free testosterone response to a given dose look larger in percentage terms, since more SHBG suppression is occurring.
Injection frequency. Splitting a biweekly dose into weekly (or twice-weekly subcutaneous) injections reduces the peak-to-trough swing in free testosterone compared with a less frequent schedule at an equivalent total weekly dose, which can reduce symptom cycling between doses.
Concurrent medications and conditions. Thyroid hormone replacement can raise SHBG and blunt the free testosterone response to a fixed dose. Conditions or medications that suppress SHBG can do the opposite. Any of these interactions should prompt a clinician to interpret free testosterone in the context of a concurrent SHBG measurement rather than assuming the testosterone dose alone explains a change.

A newer randomized trial has examined testosterone treatment outcomes specifically in prostate cancer survivors with hypogonadism, a population that historically was excluded from testosterone therapy given oncologic concerns (Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial). This line of research is relevant to how selectively testosterone therapy is offered and monitored in higher-risk populations; readers in this category should discuss candidacy and monitoring directly with their oncology and endocrinology teams rather than extrapolating standard hypogonadism protocols.

What is established, what is plausible, and what is not established

Established: Testosterone cypionate raises both total and free testosterone in hypogonadal men. Free testosterone typically rises more than total testosterone on a proportional basis because of SHBG binding-site saturation. Trough timing (drawing blood just before the next injection) is necessary for an interpretable result on an injectable regimen. Direct analog free testosterone immunoassays are less reliable than equilibrium dialysis or calculated free testosterone, especially at low concentrations. Erythrocytosis is a recognized, dose-related side effect of testosterone therapy that must be tracked separately from free testosterone.

Plausible but not precisely quantified here: The specific fold-increase in free testosterone for a given dose, the exact percentage SHBG suppression over a given treatment duration, and the exact target pg/mL range by assay type vary across studies and assay platforms. Any number presented as a universal target or expected multiple should be checked against current guideline text and the reporting lab's own reference range before being used for an individual dosing decision.

Not established from the material available here: Long-term cardiovascular outcome data specific to free testosterone targets (as opposed to total testosterone or symptom-based dosing) are not settled by a single source, and cardiovascular safety findings from large testosterone trials should be confirmed against the primary trial publications rather than a secondary summary.

When to seek urgent care rather than wait for a routine lab

Chest pain, shortness of breath, sudden severe headache, one-sided weakness, or symptoms of a blood clot (leg swelling and pain, or sudden calf tenderness) in someone on testosterone therapy warrant emergency evaluation rather than waiting for a scheduled lab draw. A very high hematocrit found incidentally should be discussed with the prescribing clinician promptly rather than self-managed.

Frequently asked questions

Does testosterone cypionate raise free testosterone?

Yes. Testosterone cypionate raises free testosterone in hypogonadal men, typically more than it raises total testosterone on a percentage basis, because SHBG binding capacity becomes saturated. The exact multiple varies by patient, dose, and assay.

Does testosterone cypionate ever lower free testosterone?

No, it does not lower free testosterone directly. If a free testosterone level drops while on a stable dose, the more likely explanations are rising SHBG from another medication or condition (for example thyroid hormone, anticonvulsants, or hyperthyroidism), inconsistent trough timing, or assay variability, and this should be reviewed with a clinician.

When should free testosterone be checked on testosterone cypionate?

At trough, meaning just before the next scheduled injection: around day 6 to 7 on a weekly protocol or day 12 to 14 on a biweekly protocol. Checking at a random time or shortly after an injection will overestimate the level.

Is a direct free testosterone blood test reliable?

Direct analog immunoassays for free testosterone are generally considered less accurate, especially at low concentrations. Equilibrium dialysis or a calculated free testosterone value (from total testosterone, SHBG, and albumin) are preferred.

Why is my free testosterone high but total testosterone looks normal on TRT?

This pattern usually reflects low SHBG, which can occur with obesity, insulin resistance, or SHBG suppression from testosterone therapy itself. Low SHBG means more testosterone circulates unbound, so free testosterone can be proportionally high even when total testosterone looks unremarkable.

Is free testosterone or total testosterone more important for dosing?

Free testosterone is generally considered more clinically informative when SHBG is abnormal, since it better reflects the biologically active hormone. In men with normal SHBG, total and free testosterone usually move together closely enough that either can guide dosing under a clinician's supervision.

What happens to free testosterone if testosterone cypionate is stopped?

Free testosterone declines over roughly two to four weeks as the injected depot clears, and SHBG gradually returns toward its pre-treatment level. Recovery of the body's own testosterone production afterward is variable and can take considerably longer, depending on how long therapy was used and the individual's hypothalamic-pituitary-testicular function.

References

Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial, https://pubmed.ncbi.nlm.nih.gov/42113507/

Other claims in this article reflect general patterns described across endocrinology and andrology literature on SHBG physiology, testosterone pharmacokinetics, and TRT monitoring. Specific numeric figures (fold-increases, exact pg/mL targets, percentage changes in SHBG) should be verified against current primary literature and current guideline text before being used for an individual patient's dosing decision, since the source citations originally associated with those figures could not be confirmed as accurate matches for this draft.